The Company acquired exclusive China rights for the development and distribution of a novel formulation of Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting.

Clinical Development Status

CASI intends to advance the development, import drug registration, and market approval of this product in China.